ArticleBMC cancer2026
Efficacy of SLNB in early endometrial adenocarcinoma in China: a retrospective cohort study based on inverse probability of treatment weighting.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEndometrial cancer significantly impacts women’s reproductive health and quality of life, with lymph node metastasis serving as a crucial prognostic factor. Given the low metastasis rate, not all early-stage patients require lymph node dissection. The NCCN upgraded Sentinel Lymph Node Biopsy (SLNB) technology to Class 2A evidence. However, the applicability of SLNB for Chinese patients remains uncertain. This study evaluates the efficacy and safety of SLNB in a Chinese population.
methodsA retrospective cohort study was conducted at Guangdong Provincial Hospital of Chinese Medicine from August 2019 to December 2022, involving 166 early-stage endometrial adenocarcinoma patients. Of these, 137 patients were assessed as moderate to high-differentiated endometrioid adenocarcinoma. Patients were divided into Sentinel Lymph Node Biopsy (SLNB, N = 43) and systematic lymph node dissection (SLND, N = 94) groups, with a median follow-up time of 39 (24, 55) months. Primary outcomes were postoperative disease progression-free survival and one-month complication rates, with secondary endpoints including surgical parameters and quality of life indicators.
resultDuring the follow-up(median follow-up time 39 months), 1 recurrence occurred in the SLNB group, with no recurrences in the SLND group. Sentinel Lymph Node Biopsy (SLNB) showed no statistically significant differences compared with traditional Sentinel Lymph Node Dissection (SLND) in oncological assessment, with no significant variations in postoperative pathological staging (β = 0.80, 95%CI: -1.29 to 2.90, p = 0.455), pathological grading (β = -0.115, 95%CI: -0.99 to 0.76, p = 0.800), and additional treatment evaluation (β = -0.214, 95%CI: -1.52 to 1.09, p = 0.749), with one recurrence in the SLNB group during follow-up. SLNB significantly improved surgical indicators: operation time reduced by 85.13 min (p < 0.001), blood loss decreased by 44.82 ml (p < 0.001), hospital stay shortened by 1.19 days (p = 0.030), with significantly lower postoperative day 1 pain scores. At 6 h post-surgery, both groups showed significant BADL decline (β = -21.53, 95%CI: -25.7 to -17.4, p < 0.001), with less functional impairment in the SLNB group and significantly shorter urinary catheter placement time (β = + 1.24, 95%CI: 0.90 to 1.59, p < 0.001). Complication analysis revealed significantly higher rates of lymphatic reflux obstruction (β = 18.22, 95%CI: 17.38 to 19.05, p < 0.001) and intestinal obstruction (β = 18.17, 95%CI: 16.16 to 20.17, p < 0.001) in the SLND group, suggesting a marked advantage of SLNB in complication management.
conclusionFor early-stage endometrial cancer patients with moderate to high differentiation and lesions confined to the inner half of the myometrium, SLNB demonstrates safety and efficacy as a minimally invasive alternative, significantly improving surgical outcomes and patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.